论文部分内容阅读
目的:对培哚普利治疗充血性心力衰竭(cHF)的疗效和安全性作出评价。方法:108例心力衰竭患者随机分为对照组54例(常规治疗)及治疗组54例(培哚普利+常规治疗),疗程6周,观察两组治疗前后的心功能及生化指标SV、CO、LVEF、LVMI、UAER、BUN、SCr的变化情况并作统计学分析。结果:治疗组总有效率79.63%,对照组总有效率38.89%(P<0.01)。两组SV、CO、LVEF、UAER、BUN、SCr治疗前后都呈统计学差异(P<0.01,P<0.05),LVMI也有轻度改善(P<0.05)。结论:培哚普利是一高效,安全的治疗心力衰竭药物。
Objective: To evaluate the efficacy and safety of perindopril in the treatment of congestive heart failure (cHF). Methods: One hundred and eighty patients with heart failure were randomly divided into control group (54 cases) and treatment group (54 cases) (perindopril group and routine treatment group) for 6 weeks. Before and after treatment, the cardiac function and biochemical indexes SV, CO, LVEF, LVMI, UAER, BUN, SCr changes and make statistical analysis. Results: The total effective rate was 79.63% in the treatment group and 38.89% in the control group (P <0.01). The levels of SV, CO, LVEF, UAER, BUN and SCr in both groups were significantly different before and after treatment (P <0.01, P <0.05), LVMI also slightly improved (P <0.05). Conclusion: Perindopril is an effective and safe drug for heart failure.